McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
Why McKesson (MCK) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
McKesson Stock Gains 34.1% YTD: What's Driving the Rally?
MCK continues to gain because of robust segmental performance and raised fiscal 2025 guidance.
MCK Stock Down Despite Latest Partnership to Boost SCD Treatment
The availability of the FDA-approved drug via McKesson's cell and gene therapies business is expected to give patients improved treatment options for SCD.
All You Need to Know About McKesson (MCK) Rating Upgrade to Buy
McKesson (MCK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
McKesson (MCK) Is Considered a Good Investment by Brokers: Is That True?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Investors Heavily Search McKesson Corporation (MCK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
Here is Why Growth Investors Should Buy McKesson (MCK) Now
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why McKesson (MCK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network
I reiterate a 'Strong Buy' on McKesson, driven by growth from GLP-1 medications and a robust oncology network business, with a fair value of $696 per share. McKesson's acquisition of a 70% interest in Florida Cancer Specialists enhances its oncology network, expanding to 3,300 providers across 31 states. Strong Q2 results with 21% revenue growth and raised EPS guidance to $32.40-$33.00, driven by specialty distribution and retail national account customers.
MCK Stock Gains as Q2 Earnings & Sales Top Estimates, '25 EPS View Up
McKesson's second-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
These Analysts Boost Their Forecasts On McKesson Following Upbeat Earnings
McKesson MCK reported better-than-expected second-quarter financial results on Wednesday.
